Investment Thesis
Aethlon Medical is in severe financial distress with minimal revenue generation ($97.1K) while burning significant cash (-$5.2M operating cash flow). The company is unprofitable with negative net margins exceeding -5400%, operating margins of -5523%, and deteriorating returns on equity (-78.5%) and assets (-65.4%). Despite adequate liquidity currently, the company's burn rate will exhaust cash reserves within 16 months without revenue acceleration or capital injection.
AEMD Strengths
- Strong liquidity position with cash-to-assets ratio of 86% and current ratio of 5.68x
- Zero long-term debt provides financial flexibility and no refinancing risk
- Minimal capital expenditure requirements suggest asset-light business model
AEMD Risks
- Critical revenue shortfall with only $97.1K in annual revenue indicating failed market traction or commercialization
- Severe cash burn of $5.2M annually will deplete $7.0M cash reserves in approximately 16 months without intervention
- Deeply unprofitable operations with -$11.01 diluted EPS and no clear path to profitability based on current business execution
- Negative returns on equity (-78.5%) and assets (-65.4%) indicate shareholder capital destruction
- Operating losses of -$5.4M dwarf minimal revenue, suggesting fundamental business model failure
Key Metrics to Watch
- Quarterly revenue growth and pipeline development indicators
- Monthly cash burn rate and runway remaining before capital depletion
- Operating expense reduction initiatives and path to cash flow breakeven
- Clinical trial progress or FDA approvals for core therapeutic platforms
- Insider trading activity pattern and confidence signals from management
AEMD Financial Metrics
AEMD Profitability Ratios
AEMD Balance Sheet & Liquidity
AEMD 5-Year Financial Trend
5-Year Trend Summary: AETHLON MEDICAL INC's revenue has declined by 12% over the 5-year period, indicating business contraction. The most recent EPS of $-38.87 indicates the company is currently unprofitable.
AEMD Growth Metrics (YoY)
AEMD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$2.0M | $-0.12 |
| Q1 2023 | N/A | -$2.1M | $-0.14 |
| Q3 2022 | $17.1K | -$1.4M | N/A |
| Q2 2022 | N/A | -$1.4M | $-0.13 |
| Q3 2021 | $413.5K | -$819.6K | N/A |
| Q2 2021 | N/A | -$1.4M | N/A |
| Q1 2021 | N/A | -$1.4M | N/A |
| Q3 2020 | N/A | -$819.6K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AEMD Capital Allocation
AEMD SEC Filings
Access official SEC EDGAR filings for AETHLON MEDICAL INC (CIK: 0000882291)